Virtu Financial’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Virtu Financial’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-11,868	Closed	-$55K	–	1802
2020 Q2	$55K	Buy	+11,868	New	+$61.5K	0.01%	994
2019 Q4	$43K	Buy	+8,626	New	+$55.8K	﹤0.01%	1224
2019 Q3	–	Sell	-3,168	Closed	-$23K	–	2032
2019 Q2	$23K	Buy	3,168 +2,123	+203%	+$15.5K	﹤0.01%	1334
2019 Q1	$8K	Sell	1,045 -7,859	-88%	-$73.9K	﹤0.01%	1349
2018 Q4	$71K	Buy	8,904 +1,385	+18%	+$16.6K	﹤0.01%	1217
2018 Q3	$116K	Buy	+7,519	New	+$90.6K	0.01%	1170
2018 Q1	–	Sell	-13,087	Closed	-$133K	–	2943
2017 Q4	$133K	Buy	+13,087	New	+$158K	0.01%	1828

Other funds holding IDXG

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFG

Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Virtu Financial's IDXG Position: Q3 2020 in Review

Virtu Financial sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q3 2020, closing a stake of 11,868 shares — an estimated $55K sold.

Virtu Financial first reported a position in IDXG in Q4 2017 and held it in 7 quarters. The position peaked at $133K in Q4 2017. 18 funds tracked by Wall St. Rank hold IDXG as of Q3 2020.

Virtu Financial reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Virtu Financial sold 11,868 Interpace Biosciences, Inc. Common Stock shares in Q3 2020, an estimated $55K.
Virtu Financial first reported a position in Interpace Biosciences, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
Virtu Financial's Interpace Biosciences, Inc. Common Stock position peaked at $133K in Q4 2017.
18 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q3 2020.

Based on Virtu Financial's 13F filing for Q3 2020, filed 11 Dec 2020.